Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.106
+0.004 (3.52%)
Mar 9, 2026, 1:51 PM EDT - Market open
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,582,750
Market Cap
5.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Lunai Bioworks | 29 |
| Processa Pharmaceuticals | 10 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Can-Fite BioPharma | 5 |
| Xenetic Biosciences | 2 |
| Cyclerion Therapeutics | 1 |
QNCX News
- 25 days ago - Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Benzinga
- 26 days ago - Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
- 27 days ago - Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Business Wire
- 5 weeks ago - Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
- 5 weeks ago - Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - Business Wire
- 2 months ago - Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
- 3 months ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire